5 stories mentioning AHCOUpdated 9d ago
Every FINWIRES story that references AHCO, newest first.
AdaptHealth (AHCO) has an average rating of buy and mean price target of $9.86, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $6.26, Change: $-0.24, Percent Change: -3.65%
Healthcare stocks were lower late Tuesday afternoon, with the NYSE Healthcare Index down 0.7% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.3%.The iShares Biotechnology ETF (IBB) climbed 2%.In corporate news, AdaptHealth (AHCO) reported a Q2 loss Tuesday, with revenue below market expectations. The company also lowered its full-year 2026 sales guidance. Its shares fell 37%.AbbVie (ABBV) has commenced a $10 billion investment-grade bond sale to help finance its pending acquisition of Apogee Therapeutics (APGE), Bloomberg reported. The offering, which includes bonds maturing in two to 40 years, has drawn about $63 billion of peak demand, the report said. AbbVie shares were down 0.4%.BioNTech (BNTX) shares shed 0.5% after it reported a wider Q2 adjusted loss and lower revenue, and cut its 2026 revenue guidance.Merck (MRK) and Pfizer (PFE) raised their respective full-year sales outlooks on Tuesday, as both pharmaceutical giants logged better-than-expected sales for Q2. Merck shares rose 0.6%, and Pfizer added 1.5%.
Better Home & Finance (BETR) expects annualized cost cuts to exceed $45 million by year-end, from the $25 million target previously set out, it said late Monday.The firm appointed board member Daniel Lewis as interim chief executive officer, effective immediately. Lewis succeeds Founder Vishal Garg, who has mutually agreed with the board to transition from the CEO role, the company said.Shares slumped 36% as intraday trading volume jumped to over 2.4 million from a daily average of about 386,000.AdaptHealth (AHCO) reported a Q2 loss Tuesday, with revenue below market expectations. The company also lowered its full-year 2026 sales guidance.Shares sank nearly 40%, with intraday trading volume rising to over 13.6 million from a daily average of roughly 1.4 million.Aptiv (APTV) reported Q2 adjusted earnings Tuesday above market expectations while sales missed consensus, and the company also cut its full-year 2026 outlook.Shares slumped 18% as intraday trading volume climbed to over 9.3 million from the stock's daily average of about 3.43 million.Price: $17.62, Change: $-9.68, Percent Change: -35.46%
AdaptHealth's (AHCO) increased spending on labor that weighed on its Q1 results ensured the "smooth" rollout of a major capitated contract in the home medical equipment space, RBC Capital Markets said in a note Friday.AdaptHealth is now well positioned to extend the relationship beyond the initial five-year period, while the new contract serves as a proof of concept that could attract additional large-scale capitated partners, the investment firm said.Management said the $12 million labor headwind includes $8 million variable labor cost to boost the capitated go-live process and $4 million of temporarily high wages and benefits from "duplicative regional onboarding," the note said.The $8 million variable labor cost is likely to normalize by the end of Q2, while the $4 million will likely decrease as the operating model right-sizes, RBC said.RBC kept AdaptHealth's outperform rating and increased the price target to $15 from $13.Shares of AdaptHealth were up 0.7% in Monday trading.Price: $11.38, Change: $+0.07, Percent Change: +0.66%
AdaptHealth (AHCO) reported Tuesday Q1 loss of $0.12 per diluted share, widening from a loss of $0.05 a year earlier.Analysts surveyed by FactSet expected loss of $0.01.Net revenue for the quarter ended March 31 was $819.8 million, compared with $777.9 million a year earlier.Analysts surveyed by FactSet expected $796.6 million.The company raised its 2026 revenue to be in a range of $3.45 billion to $3.52 billion from $3.44 billion to $3.51 billion previously. Analysts surveyed by FactSet expect $3.46 billion.Shares of the company were down more than 14% in Tuesday's premarket activity.Price: $11.10, Change: $-1.94, Percent Change: -14.88%
